What Is Cryptide? Definition and What Research Reports

A cryptide (from cryptic + peptide) is a short, biologically active peptide whose sequence is concealed within a larger parent protein and which only acquires measurable activity after proteolytic processing liberates it from that protein. The parent protein usually has a completely unrelated function — oxygen handling, lipid transport, catalysis, cell-wall signalling — so the cryptide is described as "encrypted" in a sequence that was not obviously a peptide-hormone precursor. Cryptides are therefore defined by their origin and mode of release rather than by a shared structure, receptor or effect. The term is used across mammalian immunology, plant biology, venom biochemistry and antimicrobial peptide research.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any health or treatment question. Nothing here describes a protocol, and the peptides discussed below are laboratory research subjects, not consumer products.

What class of molecule is a cryptide?

Cryptides are peptides — typically a few residues to a few dozen residues long — and they are a functional category, not a chemical family. Three features are generally used to identify one:

• It is a fragment. The sequence exists inside a longer, already-characterised protein.
• It is released by cleavage. Proteases, cell damage, digestion or processing enzymes expose the fragment.
• It has an activity the parent protein does not. The liberated fragment binds a receptor, kills microbes, or inhibits an enzyme independently of the parent molecule's job.

Because of that third criterion, cryptides are often contrasted with "classical" peptides such as insulin or GLP-1 analogues, which arise from dedicated precursor proteins whose purpose is to generate a signalling peptide. A cryptide, by contrast, is an activity that was latent in a housekeeping or structural protein.

Where cryptides come from

Mitochondrial proteins

The best-characterised mammalian cryptides come from mitochondrial respiratory-chain proteins. Researchers purified and characterised mitocryptide-2 as a novel cryptide derived from mitochondrial cytochrome b that activated neutrophils, as the 2009 report in the Journal of Immunology described. A separate investigation isolated and identified additional neutrophil-activating cryptides hidden within mitochondrial cytochrome c, indicating that more than one respiratory-chain protein can harbour such sequences (Protein and Peptide Letters, 2012).

Plasma and lipid-transport proteins

Cryptides have also been mapped inside circulating proteins. A 2020 study identified antimicrobial cryptides encrypted in human apolipoprotein B and examined them as candidate agents against antibiotic-resistant bacteria relevant to cystic fibrosis (International Journal of Molecular Sciences, 2020).

Plant precursor proteins

In plant science, Rapid Alkalinization Factor (RALF) has been described as a cryptide that regulates developmental and stress responses, according to a 2025 review in Plant Science. This illustrates that the concept is not restricted to animal immunology.

Venom enzymes

Venoms are another source. Researchers characterised a novel cryptide derived from a Bothrops cotiara venom metalloproteinase and reported that it inhibited angiotensin-converting enzyme activity in vitro (Biochimie, 2024).

How the term is used in peptide research

In the literature, "cryptide" functions mainly as a research framing device. It signals that a peptide's activity was discovered by mining an existing proteome rather than by designing a molecule from scratch. That framing shapes three recurring research activities:

1. Discovery and identification. A 2018 review catalogued identification methods for cryptic antimicrobial peptides and summarised current knowledge of their immunomodulatory properties, describing how candidate sequences are found inside parent proteins and then tested (Current Pharmaceutical Design, 2018).
2. Minimal-structure mapping. Work on mitocryptide-2 identified the minimum structure required for specific activation of formyl peptide receptor 2 (FPR2) and reported that physiological C-terminal cleavages could shift receptor preference from FPR2 toward FPR1, a phenomenon the authors framed as possible receptor switching (International Journal of Molecular Sciences, 2021).
3. Tool generation. Because cryptides are fragments of abundant proteins, distinguishing the free peptide from its parent requires selective reagents. One group generated monoclonal antibodies against mitocryptide-2 as a strategy for investigating the biological roles of cryptides (Journal of Peptide Science, 2017), and a related report described the successful acquisition of a neutralizing monoclonal antibody against mitocryptide-1, another neutrophil-activating peptide (Biochemical and Biophysical Research Communications, 2015).

What the published literature reports

Across the cited papers, the reported activities cluster into immune-cell signalling, antimicrobial action and enzyme modulation. Mitocryptide-2 was reported to act as a specific endogenous agonist for formyl-peptide receptor-like 1 (FPRL1/FPR2) in a 2011 study in Biochemical and Biophysical Research Communications. Building on the observation that mitochondrial cryptides are N-formylated, a 2016 article asked whether endogenous N-formylated peptides including mitocryptide-2 are components of mitochondrial damage-associated molecular patterns (Biopolymers, 2016). Earlier work on cryptide signalling reported that amphiphilic peptides triggered exocytotic mechanisms in mast cells, linking peptide physicochemical character to degranulation-type responses (Biochemical and Biophysical Research Communications, 2008).

Cryptide vs. related terms

• Cryptide vs. peptide fragment: every cryptide is a fragment, but a fragment is only called a cryptide when it shows activity that is independent of the parent protein.
• Cryptide vs. antimicrobial peptide (AMP): the categories overlap. "Cryptic antimicrobial peptides" are AMPs encrypted in larger proteins, and the 2018 review treated them as a distinct discovery class with immunomodulatory as well as bactericidal properties (Current Pharmaceutical Design, 2018).
• Cryptide vs. DAMP: DAMPs are molecules released by damaged cells that alert the immune system; the 2016 Biopolymers article explicitly posed the question of whether mitochondrial cryptides belong to that group (PMID 26600263).
• Mitocryptide: a subcategory naming cryptides of mitochondrial origin, such as mitocryptide-1 and mitocryptide-2 (Biochemical and Biophysical Research Communications, 2015).

Adverse Events: What Studies Report

The verified literature on cryptides consists of discovery, receptor-characterisation, antibody-generation and in-vitro activity studies rather than human trials, and none of the cited papers reported adverse events in people. Because the reported effects include activation of neutrophils and mast-cell exocytotic responses (PMID 18657517), researchers have discussed these peptides largely in the context of inflammation biology; the 2016 review framed mitochondrial cryptides as candidate damage-associated signals rather than as therapeutic agents with a defined safety profile (PMID 26600263). No tolerability, dosing or human exposure data appear in the papers cited on this page.

Limitations of the current evidence

Three limitations recur. First, the field is heterogeneous: "cryptide" spans plant signalling peptides (Plant Science, 2025) and snake-venom enzyme fragments (Biochimie, 2024), so findings rarely generalise between systems. Second, detecting endogenous cryptides is technically hard, which is why researchers invested in selective monoclonal antibodies as investigative tools (Journal of Peptide Science, 2017). Third, activity can depend on exact sequence boundaries, since the study of mitocryptide-2 reported that C-terminal cleavage altered which formyl peptide receptor the peptide preferred (PMID 33920954). Readers comparing sources should check which parent protein, species and assay a given paper used before treating any statement about "cryptides" as general.

References

• Mitocryptide-2: purification, identification, and characterization of a novel cryptide that activates neutrophils (Journal of Immunology, 2009)
• Mitocryptide-2, a neutrophil-activating cryptide, is a specific endogenous agonist for formyl-peptide receptor-like 1 (Biochemical and Biophysical Research Communications, 2011)
• Isolation and identification of novel neutrophil-activating cryptides hidden in mitochondrial cytochrome C (Protein and Peptide Letters, 2012)
• Successful acquisition of a neutralizing monoclonal antibody against a novel neutrophil-activating peptide, mitocryptide-1 (Biochemical and Biophysical Research Communications, 2015)
• Mitochondrial protein-derived cryptides: Are endogenous N-formylated peptides including mitocryptide-2 components of mitochondrial damage-associated molecular patterns? (Biopolymers, 2016)
• Generation of monoclonal antibodies against mitocryptide-2: toward a new strategy to investigate the biological roles of cryptides (Journal of Peptide Science, 2017)
• Cryptic Antimicrobial Peptides: Identification Methods and Current Knowledge of their Immunomodulatory Properties (Current Pharmaceutical Design, 2018)
• Cryptides Identified in Human Apolipoprotein B as New Weapons to Fight Antibiotic Resistance in Cystic Fibrosis Disease (International Journal of Molecular Sciences, 2020)
• Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2-Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages (International Journal of Molecular Sciences, 2021)
• A novel metalloproteinase-derived cryptide from Bothrops cotiara venom inhibits angiotensin-converting enzyme activity (Biochimie, 2024)
• Rapid Alkalinization Factor - A cryptide regulating developmental and stress responses (Plant Science, 2025)
• Cryptide signaling: Amphiphilic peptide-induced exocytotic mechanisms in mast cells (Biochemical and Biophysical Research Communications, 2008)